News | April 28, 2026
Jagsonpal Pharma profit surges 31% in Q4
Rs. 40 cr buyback, 200% dividend announced
Rs. 40 cr buyback, 200% dividend announced
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Collaboration integrates SmartChip PCR technology with cloud-based analytics to enable faster, standardised monitoring of antimicrobial resistance
Subscribe To Our Newsletter & Stay Updated
